Astria Therapeutics (NASDAQ:ATXS) Earns Outperform Rating from Analysts at JMP Securities

Research analysts at JMP Securities began coverage on shares of Astria Therapeutics (NASDAQ:ATXS) in a report issued on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $26.00 price target on the biotechnology company’s stock. JMP Securities’ price target would indicate a potential upside of 247.13% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Oppenheimer increased their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $25.67.

Astria Therapeutics Stock Up 0.4 %

NASDAQ ATXS opened at $7.49 on Friday. The firm has a market capitalization of $422.66 million, a PE ratio of -3.58 and a beta of 0.70. The stock’s 50 day moving average is $8.97 and its 200 day moving average is $10.47. Astria Therapeutics has a twelve month low of $7.16 and a twelve month high of $16.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in Astria Therapeutics by 1,043.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock worth $1,330,000 after purchasing an additional 133,379 shares during the period. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics in the second quarter worth about $171,000. Millennium Management LLC lifted its position in shares of Astria Therapeutics by 13.5% during the 2nd quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock valued at $16,763,000 after buying an additional 218,518 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Astria Therapeutics during the 2nd quarter valued at approximately $400,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Astria Therapeutics in the 2nd quarter worth approximately $2,561,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.